PCI Pharma Services Announces the Closing of Its Acquisition of LSNE
14.12.2021 17:00:00 EET | Business Wire | Press release
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire.
This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial supply and pharmaceutical packaging. PCI is now able to offer integrated large and small molecule solutions for its clinical and commercial clients, including global manufacturing capabilities in complex formulations, high potency, sterile fill-finish, and lyophilization, an important manufacturing process commonly used with injectable and biologic therapies.
Founded in 1997, LSNE has an impressive history of serving global pharmaceutical, biotechnology and medical device companies. LSNE is differentiated by its high-quality cGMP aseptic fill-finish capabilities, and expertise in and ability to scale lyophilization. LSNE brings to PCI five FDA-approved facilities in the U.S. (New Hampshire, Wisconsin) and Europe (Spain), with a sixth expecting approval early in the new year. The closing of this acquisition, along with the capital commitments for significant capacity expansion and PCI’s recently announced construction of a New England Clinical Center of Excellence, will also help create a centralized hub for its Northeast clients.
The injectable CDMO market is a high-growth segment outpacing the overall pharmaceutical outsourcing market and PCI is making significant investments, like this acquisition, to respond to the evolving industry landscape. This is PCI’s fourth acquisition in three years, reinforcing the company’s commitment to add new capabilities and scale to help its clients continue bringing life-changing therapies to patients all over the world.
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives. For more information, please visit pci.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005053/en/
Contact information
Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com / +1-212-551-4877
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 15:24:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 study. “The newly published Phase 3 data reinforce the potential of oveporexton to transform how we approach narcolepsy type 1 in clinical practice, shifting from managing individual symptoms to treating the disease itself.” NT1 is a chronic, rare neurological disease driven by orexin deficiency. As a result, people experience a range of daytime and nighttime symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle t
ZincFive Launches Next-Generation BMS, Setting a New Standard for Nickel-Zinc Battery Management9.9.2026 15:05:00 EEST | Press release
ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today launched the ZincFive BMS, a next-generation battery management system purpose-built for its NiZn chemistry, designed and assembled in the U.S. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909653032/en/ The ZincFive BMS ships standard with every ZincFive BC Series UPS Battery Cabinets, serving as the primary interface for data center operators, UPS OEM partners, and system integrators to monitor and manage ZincFive’s technology. Built on years of experience managing NiZn in real-world data center environments, ZincFive engineered the BMS around the unique characteristics of its NiZn chemistry, rather than adapting a platform designed for lithium-ion or lead-acid batteries. The result is a streamlined two-tier hardware architecture, consisting of the ZincFive Controller and ZincFive Tray Monitor, that delivers high
EIG Announces Final Close of Senior Infrastructure Debt Fund VI With $4.0 Billion Raised Across Its Direct Lending Platform9.9.2026 15:00:00 EEST | Press release
EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the final close of EIG Senior Infrastructure Debt Fund VI (“SIDF VI”) at $1.9 billion, nearly double the size of its predecessor fund. Together with $2.1 billion committed to single investor vehicles, this exceeds the strategy's original $3 billion target and reflects strong demand from investors seeking customized and evergreen exposure to senior infrastructure debt. Since launching in July 2024, SIDF VI has already committed approximately $1 billion across 16 investments, reflecting strong proprietary origination capabilities. SIDF VI seeks to make directly originated, senior secured debt investments across a broad range of sectors, including power generation, renewable energy, energy transition infrastructure, midstream and other critical infrastructure, with a primary focus on opportunities in the United States and Europe. The strategy draws on EIG's longstanding relationships wit
CoreTrust Expands International Presence, Extends Global Procurement Platform Across Europe9.9.2026 15:00:00 EEST | Press release
CoreTrust, a premier group purchasing organization (GPO) with more than 20 years of leveraging data-driven procurement intelligence and $7 billion in aggregated spend, today announced the expansion of CoreTrust Europe and its procurement platform to the United Kingdom and key European markets, including France, Germany, Ireland, the Netherlands, Sweden, and Switzerland. While members can enroll when headquartered in these seven markets, CoreTrust’s supplier partners deliver negotiated coverage that reaches members well beyond them. This strategic international expansion answers direct demand from CoreTrust’s private equity partners and multinational members to extend the company’s proven model into large, still-underserved European markets — the same demand-led path CoreTrust has followed for nearly two decades in the United States. CoreTrust Europe features nine trusted supplier partners across core indirect spend categories — including Dell, FedEx, and Lyreco, among others — enabling
Bracco Expands BubbleGen Cell Selection with CD3 + T Cell Isolation Kit9.9.2026 15:00:00 EEST | Press release
Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, today announced the expansion of its BubbleGen™ cell selection portfolio with the launch of the BubbleGen CD3+ T Cell Selection Kit. The kit, built on Bracco's microbubble technology, can enable new cell therapy workflows, including a highly scalable and cost-effective approach to manufacturing CAR-T cell therapies. This marks the first of multiple planned expansions of the BubbleGen family of cell selection solutions following the launch of its early access program in May this year. Cell selection is a critical step in cell therapy manufacturing, but the industry standard magnetic bead-based approach adds complexity, time, and cost to workflows – the enemies of scale. BubbleGen is Bracco’s response to industry demand for non-magnetic bead-based alternatives, providing a gentle selection method that minimizes cell perturbation for more reliable downstream applicatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom